Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients.

João ReisAna Rita TeixeiraAntónio Valentim GonçalvesRita Ilhão MoreiraTiago Pereira SilvaAna Teresa TimóteoRui Cruz Ferreira

Published in: Journal of clinical medicine (2022)

Dapagliflozin was associated with a significant improvement in cardiopulmonary fitness at 6 months follow-up in non-diabetic HFrEF patients.

Keyphrases